Overview
- Twist Bioscience, which reported second‑quarter results Monday, posted revenue of $110.7 million, up 19% year over year and its 13th straight quarter of sequential growth.
- The company raised full‑year sales guidance to $442 million–$447 million and kept its goal of adjusted EBITDA breakeven in fiscal Q4 2026, with third‑quarter sales projected at $114 million–$115 million.
- DNA Synthesis and Protein Solutions grew 28% to $53.3 million and next‑generation sequencing rose 12% to $57.4 million, helped by AI projects and oncology tests that track minimal residual disease after treatment.
- Profitability pressures persisted as the adjusted loss came in at $0.59 per share and the company booked $7.2 million toward a $17.1 million securities class‑action settlement that it expects insurers to cover beyond the amount recorded.
- New demand signals included an AWS partnership that names Twist the wet‑lab partner for Amazon BioDiscovery, a role that could steer more AI drug discovery work to its synthesis and protein platforms.